Sellas Life Sciences Reaches Milestone in Phase 3 REGAL Trial
Sellas Life Sciences said its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia has reached an event milestone.
Story updates
12:47:02 PM UTC
SquawkNews
BRIEF-Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acut